Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis
Jazyk angličtina Země Nový Zéland Médium print
Typ dokumentu časopisecké články, multicentrická studie
PubMed
29164493
DOI
10.1007/s40271-017-0285-1
PII: 10.1007/s40271-017-0285-1
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- kvalita života psychologie MeSH
- kvalitativně upravené roky života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- posuzování pracovní neschopnosti MeSH
- prospektivní studie MeSH
- průřezové studie MeSH
- psoriatická artritida psychologie MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- zdravotní stav * MeSH
- zdravotnické přehledy statistika a číselné údaje MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). METHODS: In this 2-year, prospective, multicentre, non-interventional study of PsA patients, EQ-5D and key clinical parameters such as Disease Activity in PsA (DAPsA), clinical DAPsA (cDAPsA; DAPsA without C-reactive protein [CRP]), and Health Assessment Questionnaire disability index (HAQ) were collected. We employed a linear mixed-effect regression model (ME) of the longitudinal dataset to explore the best predictors of QoL. RESULTS: A total of 228 patients were followed over 873 appointments/observations. DAPsA, cDAPsA and HAQ were stable and highly significant predictors of EQ-5D utilities in both cross-sectional and longitudinal analyses. The best prediction was provided using a linear ME with HAQ and cDAPsA or DAPsA. A HAQ increase of 1 point represented a decrease in EQ-5D by -0.204 or -0.203 (p < 0.0001); a one-point increase in cDAPsA or DAPsA dropped EQ-5D equally by -0.005 (p < 0.0001). The ME revealed steeper and more accurate association compared with cross-sectional regressions or non-linear models/transformations. CONCLUSIONS: This is the first mapping study conducted in PsA and we hope that our study will encourage further mapping studies in PsA. The results showed that in cases where CRP is absent, cDAPsA provides similar results to DAPsA in predicting QoL.
3rd Internal Clinic University Hospital Olomouc Olomouc Czech Republic
Clinic of Rheumatology 1st Faculty of Medicine Charles University Prague Prague Czech Republic
Department of Clinical Pharmacology Rheumatology University Hospital Plzen Plzen Czech Republic
Zobrazit více v PubMed
J Rheumatol. 2014 Apr;41(4):782-91 PubMed
Rev Bras Reumatol. 2010 Jan-Feb;50(1):31-43 PubMed
J Rheumatol. 2014 May;41(5):887-96 PubMed
Pharmacoeconomics. 1993 Nov;4(5):353-65 PubMed
Qual Life Res. 2014 Mar;23(2):431-42 PubMed
J Dermatolog Treat. 2015 Feb;26(1):23-31 PubMed
Health Policy. 1996 Jul;37(1):53-72 PubMed
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S14-8 PubMed
Patient. 2017 Aug;10 (4):455-462 PubMed
Stat Med. 1997 Oct 30;16(20):2349-80 PubMed
Ann Rheum Dis. 2016 May;75(5):811-8 PubMed
Rheum Dis Clin North Am. 2015 Nov;41(4):545-68 PubMed
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17 (2):203-211 PubMed
Eur J Health Econ. 2017 Jan;18(1):73-82 PubMed
Arthritis Res Ther. 2017 Mar 20;19(1):63 PubMed
Value Health. 2017 Jan;20(1):18-27 PubMed
J Rheumatol. 2017 Feb;44(2):193-200 PubMed
Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S126-31 PubMed
Semin Arthritis Rheum. 1973;3(1):55-78 PubMed
Eur J Health Econ. 2010 Apr;11(2):215-25 PubMed
J Clin Epidemiol. 2007 Jun;60(6):616-24 PubMed
Med Decis Making. 2012 Jan-Feb;32(1):56-69 PubMed
Value Health. 2016 Sep - Oct;19(6):704-719 PubMed
Pharmacoeconomics. 2013 Aug;31(8):643-52 PubMed
Indian Dermatol Online J. 2016 Nov-Dec;7(6):481-488 PubMed
Health Technol Assess. 2011 Mar;15(14 ):1-278 PubMed
Value Health Reg Issues. 2014 Sep;4:100-106 PubMed
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S48-50 PubMed
Ann Rheum Dis. 2016 Mar;75(3):499-510 PubMed
Open Access Rheumatol. 2017 Mar 02;9:21-28 PubMed
Eur J Health Econ. 2014 May;15 Suppl 1:S35-43 PubMed
Pharmacoeconomics. 2015 Oct;33(10 ):993-1011 PubMed
Arthritis Rheum. 2006 Aug;54(8):2665-73 PubMed
Pharmacoeconomics. 2016 Jan;34(1):59-76 PubMed
Stat Med. 1998 Jun 15;17(11):1261-91 PubMed
World J Orthop. 2014 Sep 18;5(4):537-43 PubMed
Value Health Reg Issues. 2014 Sep;4:75-81 PubMed